An official website of the United States government
Home
Name
Lanreotide Acetate
Alternate Names
BIM 23104
BIM-23014
BIM23014
Somatuline
Abbreviations
None
Category
Hormones and hormonal mechanisms
Subcategory
growth hormone releasing hormone inhibitor
Somatostatin analogue
NSC Number
None
Primary Site
stomach
intestines
pancreas
Histology
Neuroendocrine
Remarks
Lanreotide is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.
Other FDA approved indications include acromegaly and carcinoid syndrome.
Per NCCN guidelines 2025-smaler studies support use of targeted therapies including somatostatin analogues in SSTR2 positive meningioma.
Code if given for GEP-NET or SSTR2 positive meningioma.
Do not code if given for treatment of carcinoid syndrome.
Other FDA approved indications include acromegaly and carcinoid syndrome.
Per NCCN guidelines 2025-smaler studies support use of targeted therapies including somatostatin analogues in SSTR2 positive meningioma.
Code if given for GEP-NET or SSTR2 positive meningioma.
Do not code if given for treatment of carcinoid syndrome.
Coding
Please see remarks for additional information
